Just amazing results - they are starting new basket trials.
The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?
“Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency”
Another good news - voucher that they can sell or use for next approval
“With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.”
Not so sure the last few years. But what the heck. I’m new on RYTM. I’ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. I’ll do some extra digging here because the stakes are much higher. The last 3 months haven’t been bad on the other two. GLTUA Pr